Back to search

University of Ioannina

Διερεύνηση της συσχέτισης της βακτηριδιακής υπερανάπτυξης του λεπτού εντέρου και των επιπέδων των ανοσοσφαιρινών του ορού με τον ελαστογραφικά εκτιμώμενο βαθμό ηπατικής ίνωσης σε ασθενείς με χρόνιες ηπατοπάθειες καιμε την κλινική έκβαση των ασθενών με κίρρωση του ήπατος

Abstract

dc:description

Title: “Investigation of the relationship between small intestinal bacterial overgrowth(SIBO) and the levels of serum immunoglobulins with the grade of hepatic fibrosis evaluated by elastography in patients with chronic liver disease and the clinical outcome in patients with cirrhosis ”Backgound: Liver cirrhosis has been associated with small intestinal bacterial overgrowth (SIBO)and translocation of bacteria and their products, such as lipopolysaccharide, into portal and systemic circulation triggering the production of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). The systemic inflammatory reaction plays an important role in the occurrence of complications of while portal hypertension while it has been associated with the pathogenesis and progression of liver fibrosis in patients with chronic liver disease (CLD) such as alcoholic liver disease (ALD), viral hepatitis, and non-alcoholic fatty liver disease (NAFLD). In addition, the reduced clearance of intestinal bacterial antigens from liver Kupffer cells and hepatic stellate cells and their presence in the systemic circulation leads to polyclonal activation of B lymphocytes and the production of immunoglobulins. In particular, serum levels of IgG and IgA have been linked to higher grades of fibrosis inpatients with CLD. Objective: We investigated the occurrence of SIBO and its relationship with levels, markers of systemic inflammatory activity and the grade of hepatic fibrosis evaluated by elastography in patients with cirrhosis and CLD without cirrhosis due to ALD, viral hepatitis, and NAFLD. In addition, the impact of SIBO on the clinical outcome of patients with cirrhosis was assessed. Methods: We studied patients with CLD due to ALD, viral hepatitis (HBV with detectable HBVDNA and HCV), and NAFLD (with moderate-severe steatosis) who were seen in outpatient liver clinics of first division of Internal Medicine, University Hospital of Ioannina, Greece from May 2017 to May 2021. The patients were followed until liver transplantation, death or May 2024. Four groups of patients with CLD and one group of healthy volunteers were evaluated. One CLD-group included patients with cirrhosis and the other three patients without established cirrhosis. The diagnosis of ALD, viral hepatitis B and C, and NAFLD was based on current criteria. Decompensation inpatients with cirrhosis was defined as the presence of ascites, variceal bleeding or hepatic encephalopathy. We measured serum levels of IgG, IgA and IgM and evaluated markers of systemic inflammatory activity. As markers of systemic inflammation were considered the immunoglobulins and the serum levels of lipopolysaccharide-binding protein (LBP) measured with ELISA and serum levels of TNF-α and IL-6 measured with cytometry flow in the subgroup of patients with cirrhosis and ascites. SIBO was evaluated by hydrogen breath test after the administration of lactulose. We measured liver stiffness (LS) by shear wave elastography in all patients and healthy volunteers within a week after the performance of hydrogen breath test. We considered SIBO tobe present when there was an increase in breath hydrogen (peak concentration of exhaled hydrogen [PCEH]) of at least 20 ppm above the baseline value within 90 min. Spearman’s test was used for correlation of the variables of the study. The incidence of liver-related death according to the presence of SIBO was estimated using Kaplan-Meier analysis and differences were compared by the log rank test. A p value of <0.05was considered statistically significant. Results: The study included 115 patients with cirrhosis (80 with [69.5%] with ascites),108 patients with CLD (35 with ALD, 32 with chronic hepatitis [Β in 25 and C in 7] and41 with NAFLD) and 15 healthy volunteers. The occurrence of SIBO was significantly higher in patients with cirrhosis (78/115 [67.8%]) compared to those with CLD without cirrhosis in total (12/108 [11.1%%]), ALD (5/35 [14.2%]), chronic hepatitis (3/32[9.3%]), NAFLD (4/41 [9.7%]) and healthy volunteers (1/15 [6.6%]) (p<0.001 for all comparisons). The levels of IgG were significantly higher in patients with cirrhosis(1455±45 mg/dl) compared to those with CLD without cirrhosis in total (1134±38mg/dl), ALD (1152±32 mg/dl), chronic hepatitis (1102±39 mg/dl), NAFLD (1164±47mg/dl) and healthy volunteers (1094±28 mg/dl) (p<0.001 for all comparisons). The proportion of SIBO and the levels of all immunoglobulins were similar in CLD-groups without cirrhosis and healthy volunteers. The values of LS were significantly higher inpatients with cirrhosis (21.4±1 kPa) compared to those with to those with CLD without cirrhosis in total (6.8±0.6 kPa), ALD (7±0.8 kPa), chronic hepatitis (6.4±0.5 kPa), NAFLD(6.6±0.7 kPa) and healthy volunteers (4.3±0.2 kPa) (p<0.001 for all comparisons). LS was similar in CLD-groups without cirrhosis and healthy volunteers. No differences were noted in immunoglobulin levels and LS in CLD-groups without cirrhosis among patients with and without SIBO. Patients with cirrhosis and SIBO compared to those without SIBO had more advanced liver disease (Child-Pugh A/B/C: 17/38/10 vs30/16/4, p=0.001) and significantly higher proportion of ascites (90.6% έναντι 43.1%,p<0.001) and serum levels of IgG (1563±48 vs 1325±46 mg/dl, p=0.001) while the levels of IgΑ and IgΜ did not differ. The LS was significantly higher in patients with cirrhosis and SIBO compared to those without SIBO (25.8±0.9 vs 21±0.8 kPa, p=0.01).Among patients with cirrhosis and SIBO, the values of LS correlated significantly with the PCEH (r=0.395;p=0.001) and the IgG levels (r=0.462;p<0.001). The PCEH also correlated with the IgG levels (r=0.285;p=0.02). No significant correlations were noted in patients with cirrhosis without SIBO. SIBO was diagnosed in 58 (72.5%) patients with cirrhosis and ascites. The patients with ascites and SIBO had significantly higher levels of LBP (7.28±0.1 vs. 6.32±0.15 ng/mL; p<0.001) and IgG (1612±46 vs. 1377±52mg/dl, p=0.008) compared to those without SIBO. No significant differences were noted in the levels of other inflammatory markers and serum immunoglobulins among patients with and without SIBO. In patients with ascites and SIBO, the LS correlated significantly with PCEH (r=0.370;p=0.004), LBP (r=0.678; P<0.001) and IgG levels(r=0.483;p=0.009). LBP levels also correlated with LS (r=0.315;p=0.01) in these patients. No significant correlations were noted in patients without SIBO. During follow-up (35.7±1.8 months), the occurrence of decompensation/new decompensation was significantly higher in patients with SIBO compared to those without SIBO: 33/64 (51.5%) έναντι 16/56 (28.5%), p=0.01 including a higher occurrence or recurrence of ascites (21/64 [32.8%] vs. 10/56 [17.8%], p=0.06) and hepatic encephalopathy (8/64 [12.5%] vs. 2/56 [3.5%], p=0.07). The proportion of deaths was significantly higher in patients with SIBO compared to those without SIBO(19/64 [29.6%] vs. 8/56 [14.2%], p=0.04). The 5-year survival was significantly lower inpatients with SIBO than in those without SIBO (56.1% vs. 80.4%, p=0.03).Conclusions: The patients with cirrhosis due to ALD, viral hepatitis, and NAFLD, mainly those with ascites, presented higher occurrence of SIBO, which increased proportionally with the severity of cirrhosis. SIBO in patients with cirrhosis, and particularly those with ascites, was significantly related with higher IgG levels, inflammatory activity, and grade of liver fibrosis as estimated by LS. In patients with cirrhosis, SIBO was associated with worse clinical outcomes including a higher occurrence of portal hypertension complications and reduced survival. In patients with CLD without cirrhosis, the incidence of SIBO, immunoglobulin levels and LS were significantly lower than in patients with cirrhosis and similar to patients without CLD.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Despotis, Grigorios
  • Δεσπότης, Γρηγόριος

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/59093

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Despotis, Grigorios; Δεσπότης, Γρηγόριος. Διερεύνηση της συσχέτισης της βακτηριδιακής υπερανάπτυξης του λεπτού εντέρου και των επιπέδων των ανοσοσφαιρινών του ορού με τον ελαστογραφικά εκτιμώμενο βαθμό ηπατικής ίνωσης σε ασθενείς με χρόνιες ηπατοπάθειες καιμε την κλινική έκβαση των ασθενών με κίρρωση του ήπατος. University of Ioannina, 2025. http://hdl.handle.net/10442/hedi/59093